Cargando…
Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy
SIMPLE SUMMARY: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. All GISTs are potentially malignant and, in general, the risk is proportional to the tumor size. Due to their location within the muscularis propria, GISTs require an...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367571/ https://www.ncbi.nlm.nih.gov/pubmed/35954353 http://dx.doi.org/10.3390/cancers14153689 |
_version_ | 1784765848547753984 |
---|---|
author | Khan, Jaffar Ullah, Asad Waheed, Abdul Karki, Nabin Raj Adhikari, Nawaraj Vemavarapu, Lakshmi Belakhlef, Sami Bendjemil, Samy Malik Mehdizadeh Seraj, Siamak Sidhwa, Feroze Ghleilib, Intisar Foroutan, Shahin Blakely, Andrew M. Del Rivero, Jaydira Karim, Nagla Abdel Vail, Eric Heneidi, Saleh Mesa, Hector |
author_facet | Khan, Jaffar Ullah, Asad Waheed, Abdul Karki, Nabin Raj Adhikari, Nawaraj Vemavarapu, Lakshmi Belakhlef, Sami Bendjemil, Samy Malik Mehdizadeh Seraj, Siamak Sidhwa, Feroze Ghleilib, Intisar Foroutan, Shahin Blakely, Andrew M. Del Rivero, Jaydira Karim, Nagla Abdel Vail, Eric Heneidi, Saleh Mesa, Hector |
author_sort | Khan, Jaffar |
collection | PubMed |
description | SIMPLE SUMMARY: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. All GISTs are potentially malignant and, in general, the risk is proportional to the tumor size. Due to their location within the muscularis propria, GISTs require an endoscopic ultrasound for intramural sampling, although jumbo forceps sampling can be diagnostic in ulcerated lesions. GISTs usually affect people aged between 60 and 70 years, with no gender predominance. Symptomatic tumors mostly present with GI bleeding, anemia, early satiety, and abdominal fullness. The main treatment of GISTs is complete surgical resection, ideally with the preservation of tumor integrity to prevent intra-abdominal dissemination due to rupture and spillage. Advanced-stage tumors require targeted therapy with tyrosine kinase inhibitors and multidisciplinary oncologic care. ABSTRACT: Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal (GI) system. Most GISTs originate from the interstitial cells of Cajal (ICC), the pacemaker cell situated between the circular and longitudinal layers of the muscularis propria along the GI tract. In this population-based study using the SEER database, we sought to identify demographic, clinical, and pathologic factors that affect the prognosis and survival of patients with this neoplasm. Molecular genetic advances, current management guidelines, and advances in targeted therapy are discussed. Methods: Demographic and clinical data from GIST patients were retrieved from the SEER research plus database for the period 2000–2018. Statistical analysis was performed with IBM SPSS(®) v20.2 software using the Chi-square test, paired t-test, multivariate analysis, and Kaplan–Meier functions. Results: A total of 10,833 patients with GIST were identified. Most patients were between 60–74 years of age: 40%, Caucasian: 68%, and the male to female ratio was 1.1:1. The most common primary tumor sites were stomach: 63%, small intestine: 30%, rectum: 3%, and esophagus: 0.7%. When reported, the grade of differentiation was well: 38%, moderately: 32%, undifferentiated: 19%, poorly: 12%. The size of most tumors ranged between 6–10 cm: 36% and they were treated by surgical intervention: 82% and/or chemotherapy/targeted therapy: 39%. The stage was localized: 66%, advanced: 19%, and regional: 15%. The 5-year survival was 74% (95% confidence interval (95% CI) = 72.6–74.7), and the 5-year cause-specific survival 82% (95% CI = 80.7–82.6). The 5-year cause-specific survival by treatment included surgery at 86% (95% CI = 85.4–87.3), chemotherapy/targeted therapy with or without surgery at 77% (95% CI = 75.7–78.9), and radiation at 75% (95% CI = 74.5–80). On multivariable analysis tumor size > 5 cm, poorly and undifferentiated grade, age > 60, and distant metastases at presentation were associated with worse overall survival. Conclusion: GISTs comprise 1–2% of malignancies of the GI tract, usually affect male Caucasians between the ages of 60 and 74 years, most tumors occur in the stomach and small intestine, and are usually >5 cm, but still localized, at the time of diagnosis. Most tumors receive multimodality surgical and chemotherapy/targeted therapy treatment, with a 5-year overall survival of 74% and cause-specific survival of 82%. GIST patients would benefit from enrollment in large clinical trials to establish better therapy guidelines for unresectable, treatment-refractory, and recurrent tumors. |
format | Online Article Text |
id | pubmed-9367571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93675712022-08-12 Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy Khan, Jaffar Ullah, Asad Waheed, Abdul Karki, Nabin Raj Adhikari, Nawaraj Vemavarapu, Lakshmi Belakhlef, Sami Bendjemil, Samy Malik Mehdizadeh Seraj, Siamak Sidhwa, Feroze Ghleilib, Intisar Foroutan, Shahin Blakely, Andrew M. Del Rivero, Jaydira Karim, Nagla Abdel Vail, Eric Heneidi, Saleh Mesa, Hector Cancers (Basel) Article SIMPLE SUMMARY: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract. All GISTs are potentially malignant and, in general, the risk is proportional to the tumor size. Due to their location within the muscularis propria, GISTs require an endoscopic ultrasound for intramural sampling, although jumbo forceps sampling can be diagnostic in ulcerated lesions. GISTs usually affect people aged between 60 and 70 years, with no gender predominance. Symptomatic tumors mostly present with GI bleeding, anemia, early satiety, and abdominal fullness. The main treatment of GISTs is complete surgical resection, ideally with the preservation of tumor integrity to prevent intra-abdominal dissemination due to rupture and spillage. Advanced-stage tumors require targeted therapy with tyrosine kinase inhibitors and multidisciplinary oncologic care. ABSTRACT: Introduction: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasm of the gastrointestinal (GI) system. Most GISTs originate from the interstitial cells of Cajal (ICC), the pacemaker cell situated between the circular and longitudinal layers of the muscularis propria along the GI tract. In this population-based study using the SEER database, we sought to identify demographic, clinical, and pathologic factors that affect the prognosis and survival of patients with this neoplasm. Molecular genetic advances, current management guidelines, and advances in targeted therapy are discussed. Methods: Demographic and clinical data from GIST patients were retrieved from the SEER research plus database for the period 2000–2018. Statistical analysis was performed with IBM SPSS(®) v20.2 software using the Chi-square test, paired t-test, multivariate analysis, and Kaplan–Meier functions. Results: A total of 10,833 patients with GIST were identified. Most patients were between 60–74 years of age: 40%, Caucasian: 68%, and the male to female ratio was 1.1:1. The most common primary tumor sites were stomach: 63%, small intestine: 30%, rectum: 3%, and esophagus: 0.7%. When reported, the grade of differentiation was well: 38%, moderately: 32%, undifferentiated: 19%, poorly: 12%. The size of most tumors ranged between 6–10 cm: 36% and they were treated by surgical intervention: 82% and/or chemotherapy/targeted therapy: 39%. The stage was localized: 66%, advanced: 19%, and regional: 15%. The 5-year survival was 74% (95% confidence interval (95% CI) = 72.6–74.7), and the 5-year cause-specific survival 82% (95% CI = 80.7–82.6). The 5-year cause-specific survival by treatment included surgery at 86% (95% CI = 85.4–87.3), chemotherapy/targeted therapy with or without surgery at 77% (95% CI = 75.7–78.9), and radiation at 75% (95% CI = 74.5–80). On multivariable analysis tumor size > 5 cm, poorly and undifferentiated grade, age > 60, and distant metastases at presentation were associated with worse overall survival. Conclusion: GISTs comprise 1–2% of malignancies of the GI tract, usually affect male Caucasians between the ages of 60 and 74 years, most tumors occur in the stomach and small intestine, and are usually >5 cm, but still localized, at the time of diagnosis. Most tumors receive multimodality surgical and chemotherapy/targeted therapy treatment, with a 5-year overall survival of 74% and cause-specific survival of 82%. GIST patients would benefit from enrollment in large clinical trials to establish better therapy guidelines for unresectable, treatment-refractory, and recurrent tumors. MDPI 2022-07-28 /pmc/articles/PMC9367571/ /pubmed/35954353 http://dx.doi.org/10.3390/cancers14153689 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Khan, Jaffar Ullah, Asad Waheed, Abdul Karki, Nabin Raj Adhikari, Nawaraj Vemavarapu, Lakshmi Belakhlef, Sami Bendjemil, Samy Malik Mehdizadeh Seraj, Siamak Sidhwa, Feroze Ghleilib, Intisar Foroutan, Shahin Blakely, Andrew M. Del Rivero, Jaydira Karim, Nagla Abdel Vail, Eric Heneidi, Saleh Mesa, Hector Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title | Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title_full | Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title_fullStr | Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title_full_unstemmed | Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title_short | Gastrointestinal Stromal Tumors (GIST): A Population-Based Study Using the SEER Database, including Management and Recent Advances in Targeted Therapy |
title_sort | gastrointestinal stromal tumors (gist): a population-based study using the seer database, including management and recent advances in targeted therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367571/ https://www.ncbi.nlm.nih.gov/pubmed/35954353 http://dx.doi.org/10.3390/cancers14153689 |
work_keys_str_mv | AT khanjaffar gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT ullahasad gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT waheedabdul gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT karkinabinraj gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT adhikarinawaraj gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT vemavarapulakshmi gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT belakhlefsami gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT bendjemilsamymalik gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT mehdizadehserajsiamak gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT sidhwaferoze gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT ghleilibintisar gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT foroutanshahin gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT blakelyandrewm gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT delriverojaydira gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT karimnaglaabdel gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT vaileric gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT heneidisaleh gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy AT mesahector gastrointestinalstromaltumorsgistapopulationbasedstudyusingtheseerdatabaseincludingmanagementandrecentadvancesintargetedtherapy |